Trade Liberalization, IMF Conditionality, and Policy Substitution in Developing Countries
Kyklos · 2024-05 · 77 (2) · 256-284
DOI: 10.1111/kykl.12366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kyklos, online erschienen am 15.12.2023. Verfasst von Matthias Busse und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Substantial tariff reductions and increased usage of non‐tariff measures (NTMs) have been key dynamics of global trade policy in recent decades. We use highly disaggregated data on applied most favored nation tariffs, NTMs, and trade to investigate how International Monetary Fund (IMF) conditionality as a form of external pressure to reduce tariffs contributed to this dynamic in developing countries. Our results show that structural adjustment programs (SAPs) effectively lowered tariffs without increasing the usage of NTMs. A typical three‐year program containing tariff conditionality decreased tariff rates in the range of 2.0 to 3.8 percentage points in total. Furthermore, IMF programs reduced NTM initializations significantly. We also show that tariff conditionality was more effective in initiating tariff cuts for countries without previous greater globalization efforts than being a “catalyst” for ongoing liberalization efforts.
Zitieren
APA
Busse, M., & Vogel, T. (2024). Trade Liberalization, IMF Conditionality, and Policy Substitution in Developing Countries. Kyklos, 77(2), 256-284. https://doi.org/10.1111/kykl.12366
Vancouver
Busse M, Vogel T. Trade Liberalization, IMF Conditionality, and Policy Substitution in Developing Countries. Kyklos. 2024;77(2):256-284. doi:10.1111/kykl.12366
BibTeX
@article{Busse2024,
author = {Busse, Matthias and Vogel, Tim},
title = {Trade Liberalization, IMF Conditionality, and Policy Substitution in Developing Countries},
journal = {Kyklos},
year = {2024},
volume = {77},
number = {2},
pages = {256--284},
doi = {10.1111/kykl.12366}
}
EUVIMED